Enveric Biosciences, Inc. (ENVB) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+755.2%

$12.40

vs $1.45 price

Levered DCF

$13.97

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-16.34

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.1×	-0.28×	-2.41×	-2.4×	-6.73×	-57.57×	-31.98×	-3.68×
P/B	0.29×	1.7×	21.52×	4.42×	14.77×	107.63×	16.87×	5.78×
P/S	0×	0×	0×	0×	0×	0×	4.49×	1.45×
EV / EBITDA	0.4×	-0.05×	-2.36×	-2.42×	-5.6×	-58.12×	-81.32×	-9.54×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	20.4%	20.9%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-15.8%	-16.6%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-14.0%	-39.3%
Current ratio	5.38×	1.84×	1.53×	4.61×	8.51×	3.35×	0.53×	0.68×
Debt / equity	0×	0×	0×	0×	0.01×	0×	0.46×	0.48×
Interest coverage	-82,777.81×	0×	-4,435.93×	-3,802.9×	-2,514.98×	-12.62×	-9.15×	-9.79×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3361132.7%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-12363657.5%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-290.4%	-601.1%	-0.9%	-126.1%	-219.6%	-201.0%	-52.8%	-157.1%
Return on invested capital	-210.0%	-604.7%	-840.8%	-118.3%	-91.0%	-164.5%	-40.8%	-35.5%
Return on assets	-238.1%	-310.6%	-0.4%	-94.6%	-183.3%	-167.6%	-22.4%	-57.0%
Free cash flow yield	-670.1%	-285.6%	-33.5%	-27.3%	-3.7%	-1.1%	-0.4%	-4.1%
Earnings yield	-998.5%	-353.9%	-0.0%	-28.5%	-14.9%	-1.9%	-3.1%	-27.2%
Enterprise value	-$3.5M	$464.6K	$39.8M	$47.2M	$312.3M	$366.1M	$183.7M	$66M
Net debt / EBITDA	0.55×	0.24×	0.14×	0.9×	0.31×	0.25×	-1.97×	-0.55×
Cash conversion cycle (days)	-1,056	-564	-1,090	-389	-366	-2,057	4	20